Skip to main content
Premium Trial:

Request an Annual Quote

Blue Heron Wins $770K Phase II SBIR Grant for Large DNA Fragment Assembly Method

NEW YORK, March 14 (GenomeWeb News) - Blue Heron Biotechnology has been awarded a Phase II Small Business Innovation Research grant to help it develop methods for assembling very large recombinant DNA molecules, Blue Heron said yesterday.

 

The $769,250 grant was awarded by the National Institute of General Medical Science and the National Human Genome Research Institute, and follows a Phase I SBIR grant awarded in September 2004. That grant was awarded to help the company develop and demonstrate a restriction technology that allows the release of any cloned fragment, regardless of its length or the presence of conventional restriction sites.

 

Blue Heron, based in Bothell, Wash., said that if the Phase II research is successful, it will allow the company to extend its GeneMaker gene synthesis service to produce fragments of 100,000 base pairs or more.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.